Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -778.88% is in line with its 2-year average of -786.34%, around the middle of its 2-year range (-1387.54%–-91.94%).
5.29% below its 12-month average of -739.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2025 (2025-03-31): -91.94%.
EBITDA MARGIN
-778.88%
EBITDA MARGIN AVG TTM
-739.74%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.29%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Tvardi Therapeutics, Inc.
Market Cap
$10.13M
EBITDA Margin
-778.88%
TTM Avg
-739.74%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.06M
EBITDA Margin
-273136.36%
TTM Avg
-273136.36%
3Y Avg
-93106.62%
5Y Avg
-57343.52%
Market Cap
$10.06M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.21M
EBITDA Margin
-75.15%
TTM Avg
-68.19%
3Y Avg
-159.10%
5Y Avg
-185.14%
Market Cap
$9.86M
EBITDA Margin
-685.63%
TTM Avg
-612.49%
3Y Avg
-514.11%
5Y Avg
-584.57%
Market Cap
$9.83M
EBITDA Margin
-32.77%
TTM Avg
-184.94%
3Y Avg
-1690.71%
5Y Avg
-2111.15%
Market Cap
$9.71M
EBITDA Margin
-2995.72%
TTM Avg
-2995.72%
3Y Avg
-2995.72%
5Y Avg
-2995.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | $10.13M | -778.88% | -739.74% | N/A | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.06M | -273136.36% | -273136.36% | -93106.62% | -57343.52% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.21M | -75.15% | -68.19% | -159.10% | -185.14% |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | -685.63% | -612.49% | -514.11% | -584.57% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | -32.77% | -184.94% | -1690.71% | -2111.15% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A | N/A | N/A | N/A |
| MetaVia Inc. (MTVA)vs › | $9.75M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | -2995.72% | -2995.72% | -2995.72% | -2995.72% |
| Pluri Inc. (PLUR)vs › | $10.68M | -2404.23% | -2020.23% | -5031.76% | -7490.37% |
Gross Margin
0.0%
EBITDA Margin
-778.9%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-03-31 | -91.94% |
| 2024-03-31 | -1387.54% |
| 2023-12-31 | -1082.72% |
| 2023-09-30 | -583.17% |
